The association supports reclassifying ECT devices as medium risk, which would preclude the need for additional research regarding their safety and effectiveness.

CNN: FDA panel deems electroshock devices high risk

On Friday, a majority of experts on the panel expressed support for classifying ECT devices as high risk for the treatment of depression and several other conditions.

CNN: FDA panel deems electroshock devices high risk

For decades psychiatrists have used shock therapy to treat cases of depression that haven't been helped by antidepressant medications, and in recent years the treatment -- now known as electroconvulsive therapy (ECT) -- has experienced something of a revival.

CNN: FDA mulls future of electroshock therapy

Below is a long-term dividend history chart for ECT, which Dividend Channel stressed as being of key importance.

FORBES: ECT Added as Top 10 Energy Dividend Stock With 11.16% Yield

Below is a long-term dividend history chart for ECT, which the report stressed as being of key importance.

FORBES: This Stock Has A 14.42% Yield And Sells For Less Than Book

If the FDA follows the panel's advice, as it usually does, the makers of ECT devices may need to provide the agency with additional safety and efficacy evidence, like that required for prescription drugs.

CNN: FDA panel deems electroshock devices high risk

On the other side, patients' rights organizations and advocacy groups such as the Depression and Bipolar Support Alliance (DBSA) have urged the FDA not to hastily reclassify ECT devices.

CNN: FDA mulls future of electroshock therapy